Billionaire Profile
Wayne Rothbaum
Global Rank
#1362

Image: Public domain | via Wikimedia Commons

Wayne Rothbaum

CEO, Iovance Biotherapeutics
US
Real-Time Net Worth
$2.6B
As of December 2025
Age
57
Source
Biotech investing
Industry
healthcare
Citizenship
US

Biography

Wayne Rothbaum, a highly successful biotech investor, is a prominent figure in the healthcare industry. With an estimated net worth of $2.6 billion, Rothbaum's wealth stems from his expertise in biotech investing. His career includes founding Quogue Capital and co-founding cancer drug developers like Acerta Pharma, which was later acquired by AstraZeneca. Rothbaum currently serves as the executive chair of Kartos Therapeutics and Telios Pharma. He is also the largest shareholder and a board member of Iovance Biotherapeutics. Rothbaum's achievements are recognized in the book "For Blood and Money: Billionaires, Biotech and the Quest for a Blockbuster Drug." His philanthropic efforts include significant donations to SUNY Binghamton and Ohio State University.

Wealth Over Time

In-Depth Profile

Early Life and Education

Wayne Rothbaum, currently 57 years old, was born in the United States and holds a Master of Arts from George Washington University and a Bachelor of Arts/Science from the State University of New York at Binghamton. While he initially considered a career in the CIA, he later transitioned into finance in the early 1990s. Rothbaum entered the finance sector and worked at The Carson Group, a small consulting firm that advised biotech companies and investors. He quickly developed a deep understanding of biology, molecular medicine, and the complexities of clinical trials, which laid the foundation for his future success in biotech investing.

Rise to Success

Rothbaum founded the investment firm Quogue Capital in 2001, utilizing his own funds to invest. In 2012, Rothbaum co-founded and became the largest investor in Acerta Pharma, a cancer drug developer. The company's lead drug, Calquence, was approved to treat forms of lymphoma and leukemia. This investment proved highly successful when AstraZeneca acquired 55% of Acerta Pharma for $4 billion in 2016, with an agreement to acquire the remainder for nearly $2.5 billion paid between 2022 and 2024. Rothbaum has also taken a leadership role in transforming Iovance, restructuring and reorganizing its Board of Directors, senior management and overall clinical operations and strategy.

Key Business Strategies

Rothbaum's investment strategy focuses on identifying and supporting innovative biotechnology companies, particularly those developing cancer therapies. He often takes an active role in the companies he invests in, providing strategic guidance and leveraging his deep understanding of the scientific and business aspects of the industry. Rothbaum's ability to recognize the potential of early-stage companies and his commitment to developing valuable medicines for patients have been key to his success.

Philanthropy

Wayne Rothbaum has demonstrated a commitment to philanthropy through substantial donations to SUNY Binghamton for a sports complex and scholarships, as well as to Ohio State University for building housing for cancer patients.

Career Milestones

2001

Founded Quogue Capital

Established investment firm focused on life sciences.

2012

Co-founded Acerta Pharma

Co-founded and became the largest investor in Acerta Pharma, a cancer drug developer.

2016

Co-founded Kartos Therapeutics

Co-founded a cancer drug firm.

2019

Co-founded Telios Pharma

Co-founded another cancer drug firm.

Philanthropy & Social Impact

Education and Sports

SUNY Binghamton Donation

$0.3B

Donated to SUNY Binghamton for a sports complex and scholarships.

Healthcare

Ohio State University Donation

Unknown

Donated to build housing for cancer patients.